Celltrion

068270.KO

132.93 USD

0.06

+0.05%

Overview

Last close

132.93 usd

Market cap

27.24B usd

52 week high

176.66 usd

52 week low

97.64 usd

Target price

171.82 usd

Valuation

P/E

N/A

Forward P/E

31.0559

Price/Sales

14.718

Price/Book Value

2.3346

Enterprise Value

27.93B usd

EV/Revenue

14.0627

EV/EBITDA

52.9848

Key financials

Revenue TTM

1.84B usd

Gross Profit TTM

763.61M usd

EBITDA TTM

532.62M usd

Earnings per Share

N/A usd

Dividend

0.35 usd

Total assets

20,127.06B usd

Net debt

N/A usd

About

Celltrion, Inc., together with its subsidiaries, develops and produces drugs based on proteins for the treatment of oncology in South Korea. The company markets bio pharmaceuticals; generic pharmaceuticals; and covid-19 test kits. Its antibody biosimilar pipeline includes CT-P39 that is in phase 3 clinical trial for the treatment of asthma and urticaria; CT-P41, which is in phase 3 clinical trial for the treatment of osteoporosis and bone loss; CT-P42, which is in phase 3 clinical trial for the treatment of diabetic macular edema; and CT-P43 that is in phase 3 clinical trial for the treatment of psoriasis, crohn's disease, and ulcerative colitis. The company also offers CT-P47, which is in phase 3 clinical trial for the treatment of rheumatoid arthritis; and CT-P53 that is is in phase 3 clinical trial for the treatment of multiple sclerosis. Celltrion, Inc. was founded in 2002 and is headquartered in Incheon, South Korea.